- GlaxoSmithKline (GSK) joint venture company ViiV Healthcare has won FDA approval for its once-daily HIV pill Tivicay.
- In a trial released last year, a combination of Tivicay and other antiretroviral drugs reduced the HIV virus to undetectable levels in more people than Gilead's (GILD) Atripla, the world's top-selling treatment in the field. Another rival drug is Merck's (MRK) Isentress, whose sales last year were $1.5B.
- GlaxoSmithKline owns 76.5% of ViiV, Pfizer (PFE) 13.5% and Japan's Shionogi 10%.
From other sites
Video at CNBC.com (Fri, 4:24PM)
Video at CNBC.com (Fri, 1:14PM)
Video at CNBC.com (Fri, 11:40AM)
at CNBC.com (May 28, 2015)
Video at CNBC.com (May 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs